RU2001126527A - MEANS AND METHOD OF TREATMENT OR PREVENTION OF ARTERIOSCLEROSIS - Google Patents

MEANS AND METHOD OF TREATMENT OR PREVENTION OF ARTERIOSCLEROSIS

Info

Publication number
RU2001126527A
RU2001126527A RU2001126527/14A RU2001126527A RU2001126527A RU 2001126527 A RU2001126527 A RU 2001126527A RU 2001126527/14 A RU2001126527/14 A RU 2001126527/14A RU 2001126527 A RU2001126527 A RU 2001126527A RU 2001126527 A RU2001126527 A RU 2001126527A
Authority
RU
Russia
Prior art keywords
arteriosclerosis
treatment
prevention
drug
candesartan
Prior art date
Application number
RU2001126527/14A
Other languages
Russian (ru)
Other versions
RU2220723C2 (en
Inventor
Йосио Цудзита
Тосихико Фудзивара
Тосио Сада
Наоюки Маеда
Original Assignee
Санкио Компани, Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санкио Компани, Лимитед filed Critical Санкио Компани, Лимитед
Publication of RU2001126527A publication Critical patent/RU2001126527A/en
Application granted granted Critical
Publication of RU2220723C2 publication Critical patent/RU2220723C2/en

Links

Claims (6)

1. Применение, по меньшей мере, одного лекарственного препарата, выбранного из группы состоящей из CS-866, лосартана и кандесартана при производстве лекарственного средства для применения при профилактике или лечении артериосклероза.1. The use of at least one drug selected from the group consisting of CS-866, losartan and candesartan in the manufacture of a medicament for use in the prevention or treatment of arteriosclerosis. 2. Применение по п.1, где лекарственным препаратом является CS-866.2. The use according to claim 1, where the drug is CS-866. 3. Способ лечения или профилактики артериосклероза, где способ включает введение эффективного количества одного или более лекарственного препарата, выбранного из группы состоящей из CS-866, лосартана и кандесартана млекопитающему, страдающему от артериосклероза или предрасположенному к артериосклерозу.3. A method for the treatment or prophylaxis of arteriosclerosis, wherein the method comprises administering an effective amount of one or more drugs selected from the group consisting of CS-866, losartan and candesartan to a mammal suffering from arteriosclerosis or predisposed to arteriosclerosis. 4. Способ по п.3, где лекарственным препаратом является CS-866.4. The method according to claim 3, where the drug is CS-866. 5. Средство, содержащее один или более лекарственный препарат, выбранный из группы, состоящей из CS-866, лосартана и кандесартана для применения при профилактике или лечении артериосклероза.5. An agent containing one or more drugs selected from the group consisting of CS-866, losartan and candesartan for use in the prevention or treatment of arteriosclerosis. 6. Средство по п.5, где лекарственным препаратом является CS-866.6. The tool according to claim 5, where the drug is CS-866.
RU2001126527/14A 1996-07-15 1997-07-11 Agent and method for treatment or prophylaxis of arteriosclerosis RU2220723C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8/184368 1996-07-15
JP18436896 1996-07-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU99103215/14A Division RU2183128C2 (en) 1996-07-15 1997-07-11 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
RU2001126527A true RU2001126527A (en) 2003-06-27
RU2220723C2 RU2220723C2 (en) 2004-01-10

Family

ID=16152008

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2001126527/14A RU2220723C2 (en) 1996-07-15 1997-07-11 Agent and method for treatment or prophylaxis of arteriosclerosis
RU99103215/14A RU2183128C2 (en) 1996-07-15 1997-07-11 Pharmaceutical composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU99103215/14A RU2183128C2 (en) 1996-07-15 1997-07-11 Pharmaceutical composition

Country Status (19)

Country Link
US (1) US6610682B2 (en)
EP (2) EP1175902B1 (en)
KR (1) KR100540618B1 (en)
CN (2) CN1221259C (en)
AT (2) ATE306921T1 (en)
AU (1) AU714618B2 (en)
CA (1) CA2261040C (en)
CZ (2) CZ299162B6 (en)
DE (2) DE69731840T2 (en)
DK (2) DK1175902T3 (en)
ES (2) ES2250283T3 (en)
HK (1) HK1020260A1 (en)
HU (2) HU227399B1 (en)
IL (2) IL128059A (en)
NO (2) NO322314B1 (en)
NZ (1) NZ333723A (en)
PT (1) PT930076E (en)
RU (2) RU2220723C2 (en)
WO (1) WO1998002183A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047509A2 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
MXPA02010090A (en) * 2000-04-12 2003-02-12 Novartis Ag Combination of organic compounds.
DE10129725A1 (en) 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
DE10300111A1 (en) 2003-01-07 2004-07-15 Bayer Healthcare Ag Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide
EA009983B1 (en) * 2003-01-31 2008-04-28 Дайити Санкио Компани, Лимитед Medicine for prevention of and treatment for arteriosclerosis and hypertension
DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
RU2441653C2 (en) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Compositions containing nebivolol
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE102005045518A1 (en) 2005-09-23 2007-03-29 Bayer Healthcare Ag New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa
US8188270B2 (en) 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (en) 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
TWI399223B (en) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd Solid dosage form of olmesartan medoxomil and amlodipine
US20090076104A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched losartan
RU2011124948A (en) * 2008-11-19 2012-12-27 Мериал Лимитед COMPOSITIONS, INCLUDING 1-ARILPIRAZOLE ON YOURSELF OR IN COMBINATION WITH FORMAMIDINE, FOR THE TREATMENT OF PARASITIC INFECTIONS
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107617107A (en) * 2017-09-18 2018-01-23 浙江大学 A kind of anti-scar preparation of compound Angiotensin-Converting class
CN107648611A (en) * 2017-09-18 2018-02-02 浙江大学 The anti-cicatrix externally used preparation of compound Angiotensin-Converting class
CN110075304B (en) * 2019-05-29 2020-02-11 四川大学华西医院 Pharmaceutical composition for treating osteoarthritis and application thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231080A (en) 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
DE3536687A1 (en) * 1985-10-15 1987-04-16 Hoechst Ag METHOD FOR TREATING ATHEROSCLEROSIS, THROMBOSIS AND PERIPHERAL VESSEL DISEASE
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DE3925759A1 (en) * 1989-08-03 1991-02-07 Thera Patent Verwaltungs Gmbh USE OF ACE INHIBITORS FOR ATHEROSKLEROSEPROPHYLAXE
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
GB2241890A (en) 1990-03-12 1991-09-18 Squibb & Sons Inc Preventing onset of or treating protein catabolism using an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
IS1756B (en) * 1991-02-21 2000-12-28 Sankyo Company Limited Analogue method for the preparation of 1-biphenylmethylimidazole derivatives
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2118706A1 (en) * 1992-07-13 1994-01-20 Saizo Shibata Novel thiazolidinedione compounds and use thereof
JPH0741423A (en) 1993-02-24 1995-02-10 Sankyo Co Ltd Therapeutic agent for arteriosclerosis
AU6114794A (en) * 1993-02-24 1994-09-14 Sankyo Company Limited Arteriosclerosis remedy
NO303782B1 (en) * 1994-03-23 1998-08-31 Sankyo Co Thiazolidine and oxazolidine derivatives and pharmaceutical preparations containing them, as well as their use in the manufacture of medicaments
CA2186606A1 (en) * 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CN1215338A (en) 1996-04-05 1999-04-28 武田药品工业株式会社 Pharmaceutical combination containing a compound having angiotensin II and antagonisti activity

Similar Documents

Publication Publication Date Title
RU2001126527A (en) MEANS AND METHOD OF TREATMENT OR PREVENTION OF ARTERIOSCLEROSIS
CA2289717A1 (en) Novel therapy for constipation
UA49869C2 (en) NAPHTHYL-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHOD FOR TREATMENT (VARIANTS), METHOD FOR INHIBITING HUMAN FACTOR Xa OR IIa
HK1008294A1 (en) (2-4-Disulfophenyl) n-tertiary butyl nitrone its salts and their use as pharmaceutical radical trapping agents
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
RU2220723C2 (en) Agent and method for treatment or prophylaxis of arteriosclerosis
EP1688143A3 (en) Niacin-containing substained-release tablets and kits
CA2174338A1 (en) Novel pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound
IS4394A (en) Therapeutic compounds, pharmaceutically acceptable salts and compositions containing the compounds, together with their use
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
CA2283255A1 (en) Use of r-nsaid's for the prevention of alzheimer's disease
RU93047023A (en) ANIMOTENZINE-11 IMIDAZOLE ANTAGONISTS DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC USE
ES2093357T3 (en) ALOPECIA TREATMENT METHOD.
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
NZ268110A (en) Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage
CA2235951A1 (en) Novel uses of mammalian ctla-8 and related reagents
FR2714603B1 (en) Dermatological composition and its use for the preparation of a medicament.
HUP9802736A3 (en) Use of 1,4-dihydropyridine derivatives for the preparation of medicament for the prevention and therapy of atherosclerotic degradation in the arterial walls
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
CA2269031A1 (en) Treatment of urinary incontinence and compositions for use therein
NO960347L (en) Use of benzydamide in the treatment of pathological conditions caused by TNF
RU96119673A (en) METHOD FOR TREATING PAIN SYNDROME
CA2248753A1 (en) Use of olanzapine for treating excessive aggression